Literature DB >> 24616306

Are we systematically under-dosing patients with fluorouracil?

Kalpesh Patel1, Christine A Iacobuzio-Donahue1, Paul E Gormley2, Scott E Kern3, Steven C Cunningham2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24616306      PMCID： PMC4334781          DOI： 10.1200/JCO.2013.49.5044

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.

Authors:  Christina Leah Kline; Hassan S Sheikh; Angelique Scicchitano; Rebecca Gingrich; Cheryl Beachler; Niklas K Finnberg; Jason Liao; Jeffrey Sivik; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2011-10-01       Impact factor: 4.742

2.  Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue.

Authors:  P G Johnston; C M Liang; S Henry; B A Chabner; C J Allegra
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

3.  A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes.

Authors:  Jonathan R Brody; Eike Gallmeier; Kiyoshi Yoshimura; Tomas Hucl; Peter Kulesza; Marcia I Canto; Ralph H Hruban; Richard D Schulick; Scott E Kern
Journal:  Cancer Biol Ther       Date:  2006-08-02       Impact factor: 4.742

4.  Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

Authors:  Antonella Perotti; Alberta Locatelli; Cristiana Sessa; Dagmar Hess; Lucia Viganò; Giuseppe Capri; Michela Maur; Thomas Cerny; Sara Cresta; Federico Rojo; Joan Albanell; Silvia Marsoni; Irene Corradino; Lori Berk; Victor M Rivera; Frank Haluska; Luca Gianni
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

5.  Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106.

Authors:  J C Drake; C J Allegra; P G Johnston
Journal:  Anticancer Drugs       Date:  1993-08       Impact factor: 2.248

6.  Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

Authors:  Erick Gamelin; Remy Delva; Jacques Jacob; Yacine Merrouche; Jean Luc Raoul; Denis Pezet; Etienne Dorval; Gilles Piot; Alain Morel; Michele Boisdron-Celle
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

7.  A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.

Authors:  Kalpesh Patel; Sashidhar R Yerram; Nilofer A Azad; Scott E Kern
Journal:  Oncotarget       Date:  2012-07
  7 in total
  1 in total

Review 1.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.